MediPharm CBD Oil Reaches Brazilian Pharmacies Through Alko

MediPharm Labs (LABS.TO ) announced on November 10, 2026 the commercial launch in Brazil of its full-spectrum CBD oral oil through pharmaceutical partner Alko do Brasil Indústria e Comércio Ltda, making the ANVISA-authorized product available by prescription through Brazilian pharmacies.

MediPharm developed the oil and manufactures it at its pharmaceutical facility in Barrie, Ontario, which holds Good Manufacturing Practices (GMP) certification from Brazil’s health regulator, ANVISA. Alko obtained the Sanitary Authorization after submitting a regulatory dossier to the agency, with technical and regulatory support from MediPharm. The authorization covers the product’s medicinal use in Brazil.

“This launch represents the continued execution of MediPharm’s international growth strategy and further validates our position as a trusted global supplier of cannabinoid-based products manufactured under pharmaceutical quality standards,” said Chief Executive Officer Greg Hunter.

Commercial Sales Follow A Separate Regulatory Route

An ANVISA technical note signed October 2, 2026 explains the regulatory distinction behind that access. Commercial sale in Brazil requires registration as a medicine or a Sanitary Authorization under the applicable rules, a separate pathway from exceptional imports by registered individuals for personal use.

Products on the exceptional-import list are unregistered and have not had their efficacy, quality or safety evaluated by ANVISA. They cannot be distributed, resold or commercialized by companies, and their importation is strictly for the registered patient’s own use. Alko’s product instead enters through the commercial Sanitary Authorization route.

The product form also fits the framework described in the note. Cannabis plants in natura and plant parts, including flowers, are not permitted under that framework, and smoked administration is not considered a route for a health-treatment product.

MediPharm says commercialization of authorized cannabis products is focused on pharmaceutical dosage forms such as oils and other oral formulations rather than dried flower. Foreign manufacturers must also meet applicable regulatory and GMP requirements and document product quality, stability, manufacturing, regulatory compliance and post-market obligations.

Alko Launch Extends MediPharm’s Brazilian Work

The Alko launch follows a separate Brazilian partnership MediPharm announced with Laboratório Teuto on January 8, 2025. In that announcement, MediPharm said ANVISA had granted Teuto Sanitary Authorizations for two MediPharm-manufactured products, with the approvals published on December 30, 2024. Those products were full-spectrum, GMP sublingual oral solutions with pharmaceutical validation and characterization.

At the time of the Teuto announcement, initial shipments were still expected only after applicable ANVISA and Health Canada import and export permits were received. The announcement described onsite GMP inspections, pharmaceutical product filings, at least 12 months of stability testing, quality-control documentation and responses to multiple information requests over many months. The new Alko announcement instead says its product is already commercially available through pharmacies.

The Alko launch places MediPharm’s Ontario-made oil into Brazil’s commercial prescription and pharmacy-dispensing channels. For patients and the company, the practical development is legal pharmacy availability under Sanitary Authorization, within a framework that continues to treat exceptional personal imports separately and restrict plant material and smoked administration.